

**MAKE EVERY TESTING OPPORTUNITY COUNT**

# DETERMINE™ HIV EARLY DETECT

The New Standard in HIV  
Point-of-Care Testing




# A NEW STANDARD IN HIV SCREENING

Determine™ HIV Early Detect is an *in vitro*, visually read, qualitative immunoassay for the detection of antibodies (Ab) to HIV-1 and HIV-2 and the detection of non-immunocomplexed (free) HIV-1 p24 antigen (Ag) in human capillary and venous whole blood, plasma or serum.

DETECTS MORE ACUTE INFECTIONS compared to 2nd and 3rd generation tests, which helps close the window period and enables increased case finding at a time when individuals are highly infectious.



## CLOSE THE WINDOW PERIOD



### IMPROVED ACCESS

More individuals are empowered to know their status through point-of-care (POC) testing.

### EARLIER DETECTION

Leading to increased case finding of highly infectious individuals.

### RAPID, ACCURATE SCREENING

Helps close the window period and provides confidence in results at the POC.

## A PATHWAY TO IMPROVED PROGNOSIS WITH 4TH GENERATION POC TESTING



### IMMEDIATE COUNSELLING

Reducing patient loss to follow-up and allowing immediate partner notification.



### IMPROVED PROGNOSIS

Detecting human immunodeficiency virus (HIV) earlier leads to better patient outcomes.

### TIMELY PATIENT MANAGEMENT

Ability to commence appropriate treatment sooner.

### FASTER ASSESSMENT AND STAGING

Providing fast linkage to care and decreasing risk of onward transmission.

## MAKE EVERY TESTING OPPORTUNITY COUNT

ACUTE INFECTION ACCOUNTS FOR

# 10%–50%

OF ALL TRANSMISSIONS<sup>1</sup>


This acute phase of infection is associated with peak levels of viremia and a high risk of transmission.

By quickly and accurately identifying HIV-positive patients earlier, this will increase case finding and facilitate fast and appropriate linkage to care.



# THE GLOBAL DISTRIBUTION AND GENETIC DIVERSITY OF THE NINE MAJOR SUBTYPES AND RECOMBINANTS OF HIV-1

## DISTRIBUTION OF HIV-1 SUBTYPES<sup>2</sup>



● B	● CRF02_AG, OTHER RECOMBINANTS	● CRF01_AE, B	● F, G, H, J, K, CRF01, OTHER RECOMBINANTS	● A, B, AB RECOMBINANTS	
● B, C, BC RECOMBINANTS	● B, F RECOMBINANTS	● A	● C	● D	● INSUFFICIENT DATA

This map shows the global distribution and genetic diversity of the nine major subtypes, known as 'clades', and recombinants of HIV-1. Reprinted with permission from <http://www.iavireport.org>, published by the International AIDS Vaccine Initiative.

### HIV-1 ANTIGENS

HIV-1 group M subtypes A, B, C, D, F, G, H, CRF01-AE and CRF02-AG and HIV-1 group O are all detectable with Determine™ HIV Early Detect<sup>3</sup>

### HIV ANTIBODIES

HIV-1 group M subtypes A, B, C, D, F, G, H, J, K, CRF01-AE, CRF02-AG, CRF03-AB, CRF05-DF, CRF09-A/U and CRF11-cpx, HIV-1 group O and HIV-2 are all detectable with Determine™ HIV Early Detect<sup>3</sup>



Plastic capillary tubes included in SET kit only.

## PERFORMANCE

Sensitivity\* 100%

Specificity 99.72%

\*Refer to the Product Insert for the analytical sensitivity of HIV-1 p24 Antigen.

### PRODUCT INFORMATION

Method	Lateral flow
Time to results	20 minutes
Storage conditions	2°C–30°C
Sample volume	50 µL
Test shelf life	18 months
Sample types	Serum/plasma, fingerstick whole blood and venipuncture whole blood

## NEW POSSIBILITIES IN PATIENT CARE

By closing the window period, Determine™ HIV Early Detect sets a new standard in POC testing. This simple test delivers fast, accurate results in 20 minutes, introducing new possibilities in patient care.

### ORDER INFORMATION

DETERMINE™ HIV EARLY DETECT	CE MARKED	NON-CE MARKED
Determine™ HIV Early Detect 20 Test Kit	7D2846	7D2842
Determine™ HIV Early Detect 100 Test Kit	7D2847	7D2843
Determine™ HIV Early Detect SET (100 tests, plastic capillary tubes, blood lancets, and chase buffer)		7D2843SET
Chase Buffer (for 100 tests)	7D2243	7D2243
Determine™ HIV Controls (3 positives, 1 negative)	7D2253	7D2253
EDTA Glass Capillary Tubes (100)	7D2227	7D2222

## FOR MORE INFORMATION, CONTACT YOUR LOCAL REPRESENTATIVE

1. Rutstein SE, Ananworanich J, Fidler S, et al. Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. *J Int AIDS Soc.* 2017;20(1):21579. doi:10.7448/IAS.20.1.21579
2. McCutchan FE, Henry M. Jackson Foundation (Rockville, Maryland). IAVI Report. Published August 2003. <http://www.pbs.org/wgbh/pages/frontline/aids/atlas/clade.html>.
3. Determine™ HIV Early Detect Product Insert.

PRODUCT MAY NOT BE AVAILABLE IN ALL MARKETS AND IS SUBJECT TO REGULATORY APPROVAL IN REGULATED COUNTRIES.

© 2022 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model. COL-02990-02 04/22

